article thumbnail

UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21

The Pharma Data

The company, along with partners University of Nottingham and Trent University, received a British government grant to support the study. . Source link.

article thumbnail

Will people line up for a COVID-19 vaccine?

World of DTC Marketing

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. What we have right now is a collection of animal data, immune response data, and safety data based on early trials and from similar vaccines for other diseases.

Vaccine 155
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

Code Bio’s 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don’t trigger an immune response which might cause side effects or limit the potential for re-dosing.

article thumbnail

ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers?

Pharmaceutical Technology

The advent of immune checkpoint inhibition has arguably been the greatest breakthrough for the treatment of metastatic solid tumours, with durable complete responses observed across multiple cancer types. ICI therapy requires pre-existing anti-tumour T cells to be in contact with the cancer cells.

article thumbnail

Chinese tech giant Baidu licenses mRNA algorithm to Sanofi

pharmaphorum

Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs.

Licensing 105
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response. The promise of this approach means that there is now a growing pipeline of potential cancer vaccines emerging from within the portfolios of larger pharma companies and biotechs.

article thumbnail

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

The plasmid harnesses cellular machinery to create the spike protein, which is recognised as foreign by the immune system and stimulates an immune response. The company also says that it can update the vaccine very easily to deal with mutations in the virus.

DNA 98